HC Wainwright restated their buy rating on shares of Curis (NASDAQ:CRIS – Free Report) in a report published on Wednesday, Benzinga reports. They currently have a $26.00 target price on the biotechnology company’s stock. Separately, Cantor Fitzgerald restated an overweight rating on shares of Curis in a research note on Wednesday. Read Our Latest Stock […]
Curis (NASDAQ:CRIS) Receives Buy Rating from Truist Financial
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.
Curis (CRIS) Announces Additional Data from TakeAim Leukemia Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Curis (NASDAQ:CRIS) Issues Quarterly Earnings Results
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.